All Stories

  1. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia
  2. The use of cytapheresis in the treatment of infectious diseases
  3. How shall we transfuse Hippolyta?
  4. Seeing is believing: A review of apheresis therapy in the treatment of ophthalmologic disease
  5. Therapeutic plasma exchange causing (not curing) hemolysis
  6. Paired comparison of therapeutic plasma exchange using the Fenwal Amicus versus TerumoBCTSpectra Optia
  7. How I treat autoimmune hemolytic anemia
  8. Iatrogenic thyrotoxicosis and the role of therapeutic plasma exchange
  9. Therapeutic plasma exchange for perioperative management of patients with congenital factor XI deficiency
  10. Apheresis illustrated: I can see it now
  11. Red cell exchange for a case of babesiosis
  12. What are the Newer Applications for Therapeutic Apheresis in Nephrology?
  13. Differences in Chronic Intragraft Inflammation Between Positive Crossmatch and ABO-Incompatible Kidney Transplantation
  14. Outcomes of plasma exchange in patients with transplant‐associated thrombotic microangiopathy based on time of presentation since transplant
  15. National heart, lung, and blood institute state of the science symposium in therapeutic apheresis—Therapeutic apheresis in cardiovascular disease
  16. Antibody-mediated rejection despite inhibition of terminal complement
  17. The entity of immunoglobulin A–related anaphylactic transfusion reactions is not evidence based
  18. Prospective Study on the Clinical Course and Outcomes in Transfusion-Related Acute Lung Injury*
  19. American society for apheresis guidelines on the use of apheresis in clinical practice: Practical, concise, evidence‐based recommendations for the apheresis practitioner
  20. Immune Profiling to Predict Treatment Response from Extracorporeal Photopheresis in Graft-Versus-Host Disease
  21. Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis
  22. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis
  23. How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures
  24. The mechanisms of action of plasma exchange
  25. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research
  26. Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass
  27. Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell–apheresis product: implications for clinical decisions and impact on patient treatment
  28. Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation
  29. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
  30. A multicenter evaluation of a new therapeutic plasma exchange procedure
  31. Risk Factors and Outcomes in Transfusion-associated Circulatory Overload
  32. Ticlopidine‐associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR)
  33. The fifth annual therapeutic apheresis academy: Continuity and changes
  34. Randomized controlled trials in therapeutic apheresis
  35. Lot‐to‐lot variability in HLA antibody screening using a multiplexed bead‐based assay
  36. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial
  37. Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization
  38. Five-Year Outcomes in Living Donor Kidney Transplants With a Positive Crossmatch
  39. Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR)
  40. Drug-Associated Thrombotic Microangiopathies
  41. A FACTOR FOUND IN THE IGG FRACTION OF SERUM OF PATIENTS WITH PARANEOPLASTIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION CAUSES PROLIFERATION OF CULTURED HUMAN MELANOCYTES
  42. Milestones for Apheresis education
  43. Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage‐gated potassium channels: A report of five cases and review of the literature
  44. Fresh Red Blood Cell Transfusion and Short-Term Pulmonary, Immunologic, and Coagulation Status
  45. Transfusion-related acute lung injury: incidence and risk factors
  46. Low‐Density Lipoprotein Apheresis: Principles and Indications
  47. Susac syndrome: clinical characteristics and treatment in 29 new cases
  48. Apheresis in the treatment of idiopathic dilated cardiomyopathy
  49. Evidence-based guideline update: Plasmapheresis in neurologic disorders
  50. The potential role of plasma exchange as a treatment for bilateral diffuse uveal melanocytic proliferation: A report of two cases
  51. Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney
  52. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome
  53. The Impact Of Red Blood Cell Storage Duration On Short-Term Pulmonary Function And Immunologic Status In Mechanically Ventilated Patients
  54. A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization
  55. Lipid apheresis, indications, and principles
  56. Manual color monitoring to optimize hematopoietic progenitor cell collection on the Fenwal Amicus
  57. Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with al amyloidosis
  58. Apheresis medicine state of the art in 2010: American Society for Apheresis fifth special edition of the Journal of Clinical Apheresis
  59. Use of plasma exchange in patients with heparin‐induced thrombocytopenia: A report of two cases and a review of the literature
  60. Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis
  61. Hemapheresis
  62. Identification of anti-PP1Pk in a blood donor and her family: A case report following her pregnancy and review
  63. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention
  64. Polyethylene glycol antiglobulin tube versus gel microcolumn: influence on the incidence of delayed hemolytic transfusion reactions and delayed serologic transfusion reactions
  65. Cancer‐associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration
  66. Baseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation
  67. Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor cell collection to increase lymphocyte yield and reduce cross‐cellular contamination
  68. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis
  69. Thrombus formation during platelet donation
  70. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune‐mediated severe ADAMTS13‐deficiency: a report of four cases and a systematic review of the literature
  71. Transient neonatal acquired von Willebrand syndrome due to transplacental transfer of maternal monoclonal antibodies
  72. Organ Procurement Organization Compliance with 21 CFR 1271: A Challenge for Allogeneic Pancreatic Islet Cell Transplantation Programs
  73. Plasma exchange in pancreatitis due to hypertriglyceridemia
  74. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh‐frozen plasma
  75. Acquired von Willebrand syndrome: transplacental transfer of maternal monoclonal antibodies and description of peripartum management
  76. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008)
  77. The accuracy of natriuretic peptides (brain natriuretic peptide and N‐terminal pro‐brain natriuretic) in the differentiation between transfusion‐related acute lung injury and transfusion‐related circulatory overload in the critically ill
  78. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma
  79. THE ACCURACY OF NATRIURETIC PEPTIDES (BNP AND NT-PRO-BNP) IN THE DIFFERENTIATION BETWEEN TRANSFUSION-RELATED ACUTE LUNG INJURY (TRALI) AND TRANSFUSION-RELATED CIRCULATORY OVERLOAD (TACO) IN THE CRITICALLY ILL
  80. The effect of double‐ and triple‐apheresis platelet product donation on apheresis donor platelet and white blood cell counts
  81. Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study
  82. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
  83. Concentration changes to counteract the effects of bacteriological sampling on PLT yields
  84. Transfusion-related Acute Lung Injury in the Critically Ill
  85. How we approach an apheresis request for a Category III, Category IV, or noncategorized indication
  86. Reply
  87. Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A‐Agarose column: A comparison of immunoglobulin reduction using two different techniques
  88. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components*
  89. Fresh-Frozen Plasma and Platelet Transfusions Are Associated With Development of Acute Lung Injury in Critically Ill Medical Patients
  90. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis
  91. The new approach to assignment of ASFA categories—Introduction to the fourth special issue: Clinical applications of therapeutic apheresis
  92. A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy
  93. Category IV indications for therapeutic apheresis—ASFA fourth special issue
  94. The addition of decision support into computerized physician order entry reduces red blood cell transfusion resource utilization in the intensive care unit
  95. THE ADDITION OF DECISION SUPPORT INTO COMPUTERIZED PHYSICIAN ORDER ENTRY(CPOE) REDUCES RED BLOOD CELL TRANSFUSION RESOURCE UTILIZATION IN THE ICU.
  96. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers
  97. Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation
  98. Transfusion‐related acute lung injury and pulmonary edema in critically ill patients: a retrospective study
  99. Evidence-based red cell transfusion in the critically ill: Quality improvement using computerized physician order entry*
  100. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphoc...
  101. A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody
  102. Complications of donor apheresis
  103. A Comparison of Splenectomy versus Intensive Posttransplant Antidonor Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation
  104. Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD)
  105. Rheopheresis for macular degeneration: the data is not there yet to justify it
  106. Paired comparison of Gambro Trima Accel versus Baxter Amicus single‐needle plateletpheresis
  107. Transfusion of apheresis PLTs from IgA‐deficient donors with anti‐IgA is not associated with an increase in transfusion reactions
  108. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator
  109. Plasma exchange conditioning for ABO‐incompatible renal transplantation
  110. New directions in plasma exchange
  111. Cold agglutinin disease
  112. Multiple Blood Donations and Iron Deficiency in Patients With Restless Legs Syndrome
  113. Frozen preoperative autologous blood donation for heart transplantation at the Mayo Clinic from 1988 to 1999
  114. RBC Tranfusion Threshold and Outcomes in the Medical Intensive Care Uni
  115. Comparative Performance of Herpes Simplex Virus Type 1-Specific Serologic Assays from MRL and Meridian Diagnostics
  116. Absence of mutations in the HoxA10, HoxA11 and HoxD11 nucleotide coding sequences in thrombocytopenia with absent radius syndrome
  117. RBC alloantibody specificity and antigen potency in Olmsted County, Minnesota
  118. Congenital glioblastoma multiforme: a report of three cases and a review of the literature
  119. TRANSFUSION 1999;39:1097‐1103.
  120. Therapeutic apheresis in renal and metabolic diseases
  121. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions
  122. Plasma exchange treatment for CNS inflammatory demyelinating disease